Find Clinical Trials

Answer each question to find trials that best match your clinical situation. You can leave questions blank if you do not know the answer.

This search will output a list of trials for which you may be eligible based on the criteria you enter.

Matching Trials

For more detailed information please click on the clinical trial number and you will be taken to the clinicaltrials.gov website.
For a key to the icons and text used in the Results column, please click here.
To learn more about our trial annotation process, results assignments, and the criteria used to highlight drugs with promising results, please click here.

  Clinical Trial Phase Eligible Participant Official Title Location Drugs in Trial Results
NCT04377087IIPlatinum sensitive ovarian cancer with response to most recent Pt-based therapy (maintenance)Phase IIA Trial of Delayed Initiation of Olaparib Maintenance Therapy in Platinum Sensitive Recurrent Ovarian CancerPAView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
OlaparibAZD2281, LynparzaPARP inhibitorApproved in Ovarian Cancer
NCT04804007IIGerm cell tumors after treatment with high-dose chemotherapy (HDCT) and peripheral-blood stem-cell transplant (PBSCT) (maintenance)Randomized Phase 2 Trial of Maintenance Oral Etoposide or Observation Following High-dose Chemotherapy for Relapsed Metastatic Germ-Cell TumorINView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
EtoposideVePesid, Toposar, Lastet, epipodophyllotoxinTopoisomerase II inhibitor
NCT02737787IRecurrent NY-ESO-1+ ovarian cancer with CR in second or greater remissionA Phase I Study of Concomitant WT1 Analog Peptide Vaccine or NY-ESO-1 Overlapping Peptides Vaccine in Combination With Nivolumab in Patients With Recurrent Ovarian Cancer Who Are in Second or Greater RemissionNJ, NYView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NY-ESO1 OLP4 vaccineImmune response against cancer expressing NY-ESO-1Clinical Trials

If you have any questions or would like help with your search, please call us at: 858-657-0282 or email us at patientsupport@clearityfoundation.org.